Cannabis Ruderalis

thcscience_admin
Browse history interactively
← Previous edit
Content deleted Content added
VisualWikitext
Gunnanmon (talk | contribs)
149 edits
No edit summary
Ffffrr (talk | contribs)
Extended confirmed users
98,379 edits
Importing Wikidata short description: "Chemical compound" (Shortdesc helper)
 
(27 intermediate revisions by 15 users not shown)
Line 1: Line 1:
{{Short description|Chemical compound}}
{{Drugbox|
{{Drugbox
⚫
|IUPAC_name = (6aR,10aR)-6a,7,10,10a-Tetrahydro-3-[5-(1H-imidazol-1-yl)-1,1-dimethylpentyl]-6,6,9-trimethyl-6H-dibenzo[b,d]pyran-1-ol
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 435602295
⚫
| IUPAC_name = (6a''R'',10a''R'')-6a,7,10,10a-Tetrahydro-3-[5-(1''H''-imidazol-1-yl)-1,1-dimethylpentyl]-6,6,9-trimethyl-6''H''-dibenzo[''b'',''d'']pyran-1-ol
| image = O-2545.svg
| image = O-2545.svg
| width= 240
| width = 240

⚫
| CAS_number= 874745-42-3
<!--Clinical data-->
| ATC_prefix=
| tradename =
| ATC_suffix=
⚫
| PubChem=
| DrugBank=
⚫
| C=26 | H=36 | N=2 | O=2
| molecular_weight = 408.575 g/mol
| bioavailability=
⚫
| metabolism =
⚫
| elimination_half-life=
⚫
| excretion =
| pregnancy_category =
| legal_status = Unscheduled
| legal_status = Unscheduled
| routes_of_administration=
| routes_of_administration =
⚫
}}


<!--Pharmacokinetic data-->
⚫
'''O-2545''' is an [[analgesic]] [[cannabinoid]] derivative created by Organix Inc. for use in scientific research. Unlike most cannabinoids discovered to date, it is water soluble, which gives it considerable advantages over many related cannabinoids. It has high affinity for both [[cannabinoid receptor 1|CB<sub>1</sub>]] and [[cannabinoid receptor 2|CB<sub>2</sub>]] [[Receptor (biochemistry)|receptors]], with [[Dissociation constant|Ki]] values of 1.5nM at CB<sub>1</sub> and 0.32nM at CB<sub>2</sub>.<ref>Martin BR, Wiley JL, Beletskaya I, Sim-Selley LJ, Smith FL, Dewey WL, Cottney J, Adams J, Baker J, Hill D, Saha B, Zerkowski J, Mahadevan A, Razdan RK. Pharmacological characterization of novel water-soluble cannabinoids. ''Journal of Pharmacology and Experimental Therapeutics''. 2006 Sep;318(3):1230-9. PMID 16757541</ref>
⚫
| metabolism =
⚫
| elimination_half-life =
⚫
| excretion =


<!--Identifiers-->
⚫
{{cannabinoid-stub}}
| CAS_number_Ref = {{cascite|correct|??}}
⚫
| CAS_number = 874745-42-3
⚫
| PubChem =
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
| ChemSpiderID = 22938186

<!--Chemical data-->
⚫
| C=26 | H=36 | N=2 | O=2
| smiles = CC1=CC[C@H]2[C@@](Oc3c(c(cc(c3)C(CCCCn4cncc4)(C)C)O)[C@@H]2C1)(C)C
| StdInChI_Ref = {{stdinchicite|changed|chemspider}}
| StdInChI = 1S/C26H36N2O2/c1-18-8-9-21-20(14-18)24-22(29)15-19(16-23(24)30-26(21,4)5)25(2,3)10-6-7-12-28-13-11-27-17-28/h8,11,13,15-17,20-21,29H,6-7,9-10,12,14H2,1-5H3/t20-,21-/m1/s1
| StdInChIKey_Ref = {{stdinchicite|changed|chemspider}}
| StdInChIKey = RZGSWWCABDVBGX-NHCUHLMSSA-N
⚫
}}

⚫
'''O-2545''' is an [[analgesic]] [[cannabinoid]] derivative created by [[Organix Inc]]. for use in scientific research. Unlike most cannabinoids discovered to date, it is water-soluble, which gives it considerable advantages over many related cannabinoids. It has high affinity for both [[cannabinoid receptor 1|CB<sub>1</sub>]] and [[cannabinoid receptor 2|CB<sub>2</sub>]] [[Receptor (biochemistry)|receptors]], with [[Dissociation constant|''K''<sub>i</sub>]] values of 1.5&nbsp;nM at CB<sub>1</sub> and 0.32&nbsp;nM at CB<sub>2</sub>.<ref name="pmid16757541">{{cite journal | vauthors = Martin BR, Wiley JL, Beletskaya I, Sim-Selley LJ, Smith FL, Dewey WL, Cottney J, Adams J, Baker J, Hill D, Saha B, Zerkowski J, Mahadevan A, Razdan RK | title = Pharmacological characterization of novel water-soluble cannabinoids | journal = The Journal of Pharmacology and Experimental Therapeutics | volume = 318 | issue = 3 | pages = 1230–9 | date = September 2006 | pmid = 16757541 | doi = 10.1124/jpet.106.104109 | s2cid = 14864925 }}</ref>


==See also==
==See also==
* [[O-1057]]
* [[O-2113]]
* [[O-2172]]
* [[O-2372]]
* [[Tropoxane]]
* [[Tropoxane]]


==References==
==References==
{{reflist}}
<references/>


{{cannabinoids}}
{{cannabinoids}}
⚫
{{cannabinoid-stub}}
[[Category:Cannabinoids]]
[[Category:Cannabinoids]]
[[Category:Benzochromenes]]
[[Category:Benzochromenes]]

Latest revision as of 03:47, 13 April 2022

O-2545
Legal status
Legal status
  • In general: unscheduled
Identifiers
  • (6aR,10aR)-6a,7,10,10a-Tetrahydro-3-[5-(1H-imidazol-1-yl)-1,1-dimethylpentyl]-6,6,9-trimethyl-6H-dibenzo[b,d]pyran-1-ol
CAS Number
ChemSpider
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC26H36N2O2
Molar mass408.586 g·mol−1
3D model (JSmol)
  • CC1=CC[C@H]2[C@@](Oc3c(c(cc(c3)C(CCCCn4cncc4)(C)C)O)[C@@H]2C1)(C)C
  • InChI=1S/C26H36N2O2/c1-18-8-9-21-20(14-18)24-22(29)15-19(16-23(24)30-26(21,4)5)25(2,3)10-6-7-12-28-13-11-27-17-28/h8,11,13,15-17,20-21,29H,6-7,9-10,12,14H2,1-5H3/t20-,21-/m1/s1 ☒N
  • Key:RZGSWWCABDVBGX-NHCUHLMSSA-N ☒N
 ☒NcheckY (what is this?)  (verify)

O-2545 is an analgesic cannabinoid derivative created by Organix Inc. for use in scientific research. Unlike most cannabinoids discovered to date, it is water-soluble, which gives it considerable advantages over many related cannabinoids. It has high affinity for both CB1 and CB2 receptors, with Ki values of 1.5 nM at CB1 and 0.32 nM at CB2.[1]

See also[edit]

References[edit]

  1. ^ Martin BR, Wiley JL, Beletskaya I, Sim-Selley LJ, Smith FL, Dewey WL, Cottney J, Adams J, Baker J, Hill D, Saha B, Zerkowski J, Mahadevan A, Razdan RK (September 2006). "Pharmacological characterization of novel water-soluble cannabinoids". The Journal of Pharmacology and Experimental Therapeutics. 318 (3): 1230–9. doi:10.1124/jpet.106.104109. PMID 16757541. S2CID 14864925.
source: https://en.wikipedia.org/w/index.php?title=O-2545&diff=1082425479&oldid=413171597

Leave a Reply